Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma
Authors
Keywords
hepatocellular carcinoma, hepatitis C virus, tumour progression rate, sorafenib, joint modelling
Journal
JOURNAL OF HEPATOLOGY
Volume 75, Issue 4, Pages 879-887
Publisher
Elsevier BV
Online
2021-05-28
DOI
10.1016/j.jhep.2021.05.015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment
- (2019) Sarah Berhane et al. BRITISH JOURNAL OF CANCER
- Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study
- (2019) Soon Kyu Lee et al. PLoS One
- Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials
- (2019) Giuseppe Cabibbo et al. Future Oncology
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
- (2018) Roser Pinyol et al. GUT
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
- (2017) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Time-dependent efficacy of longitudinal biomarker for clinical endpoint
- (2016) Ruwanthi Kolamunnage-Dona et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
- (2015) James J. Harding et al. CANCER
- Pattern of tumor progression in liver cancer: The missing partner in trial design
- (2015) Maria Reig et al. HEPATOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
- (2013) R. Lencioni CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial
- (2013) Colin Powell et al. Lancet Respiratory Medicine
- The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma
- (2012) R. Cabrera et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- A general and simple method for obtainingR2from generalized linear mixed-effects models
- (2012) Shinichi Nakagawa et al. Methods in Ecology and Evolution
- The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
- (2011) O. Amit et al. EUROPEAN JOURNAL OF CANCER
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
- (2011) Romain Coriat et al. PLoS One
- Basic Concepts and Methods for Joint Models of Longitudinal and Survival Data
- (2010) Joseph G. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
- (2009) K. Himmelsbach et al. GUT
- Optimal Contrast Dose for Depiction of Hypervascular Hepatocellular Carcinoma at Dynamic CT Using 64-MDCT
- (2008) Yumi Yanaga et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started